DermTech, Inc. is a molecular dermatology company that focuses on skin cancer. The Company develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and customize drug treatments. The Company provides Adhesive Skin Collection Kit, which is designed to collect stratum corneum tissues of the skin from all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair. It provides Pigmented Lesion Assay (PLA), which assesses pigmented skin lesions, moles or dark skin spots for melanoma. It offers Nevome, which is the test to non-invasively identify pigmented lesions by analyzing known deoxyribonucleic acid (DNA) mutation risk factors for melanoma. The Company is also engaged in developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. It also offers ResponseTNF product and CytokineEx 17 product.